ETHYL LOFLAZEPATE

- Everything we could find out about it

Home ] [ Controlled Substances ] [ Depressants ]

Created Jun 2019 | Updated Nov 2020

ETHYL LOFLAZEPATE

  • [MEILAX]
  • [RONLAX]
  • [VICTAN]

DEA CODE 2758: Schedule 4

Ethyl loflazepate (Lof) has been used widely as a sedative and anxiolytic agent for nearly 20 years. Ethyl loflazepate was designed to be a prodrug for descarboxyloflazepate, its active metabolite. It is the active metabolite which is responsible for most of the pharmacological effects rather than ethyl loflazepate. Ethyl loflazeplate is commercialized in Mexico, under the trade name Victan. It is officially approved for the following conditions Anxiety: Post-trauma anxiety; Anxiety associated with severe neuropathic pain; Generalized anxiety disorder (GAD); Panic attack; Delirium tremens. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Accumulation of the active metabolites of ethyl loflazepate are not affected by those with renal failure or impairment. The symptoms of an overdose of ethyl loflazepate include sleepiness, agitation and ataxia. Hypotonia may also occur in severe cases. These symptoms occur much more frequently and severely in children. High doses of the antidepressant fluvoxamine may potentiate the adverse effects of ethyl loflazepate.

Ethyl loflazepate (marketed under the brand names Meilax, Ronlax and Victan) is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. In animal studies it was found to have low toxicity, although in rats evidence of pulmonary phospholipidosis occurred with pulmonary foam cells developing with long-term use of very high doses. Its elimination half-life is 51 hours - 103 hours. Belongs to the class of organic compounds known as alpha amino acid esters. Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. Ethyl loflazepate also produces an active metabolite which is stronger than the parent compound. Ethyl loflazepate was designed to be a prodrug for descarboxyloflazepate, its active metabolite. It is the active metabolite which is responsible for most of the pharmacological effects rather than ethyl loflazepate.

Ethyl loflazepate:
  • A benzodiazepine derivative
  • It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties
  • Its elimination half-life is 51 - 103 hours.
  • Its mechanism of action is similar to other benzodiazepines.

Ethyl loflazepate also produces an active metabolite which is stronger than the parent compound. Ethyl loflazepate was designed to be a prodrug for descarboxyloflazepate, its active metabolite. It is the active metabolite which is responsible for most of the pharmacological effects rather than ethyl loflazepate.

  
Vortioxetine Interaction with other Drugs - Vortioxetine is an antidepressant used for the treatment of major depressive disorder (MDD) in adults and also investigated as a treatment for generalized anxiety disorder (GAD).
Friday May 20, 2022 - medindia.net

Cyclizine Interaction with other Drugs - Cyclizine is a histamine H1 inhibitor prescribed for adults and children 6 years and above for the treatment of nausea and vomiting caused due to • Motion sickness • Surgeries • Drugs like ...
Tuesday May 11, 2021 - medindia.net

  
Depressants | Link to this page

Home ] [ Controlled Substances ] [ Sources ]


· Controlled Substances
· Depressants
· Ethyl-loflazepate